Last Updated: October 2026
Should a sponsor leave its Trial Master File with the CRO, or hold it in its own eTMF? In most cases, a sponsor-owned eTMF is the better default. It gives you direct oversight, inspector access you control, one consistent filing structure across studies and CROs, and no end-of-study transfer. A CRO-hosted TMF takes less internal effort, but it limits visibility and creates handoff risk and extra cost at closeout.
Below, we cover what you gain by owning the TMF, how the two models compare side by side, and what to look for in a system.
In this article
- Why sponsors should own the TMF
- Single source for TMF documentation
- Simplifying the use of multiple CROs
- Enhanced oversight and control
- Consistency and familiarity for internal teams
- Eliminating end-of-study transfers
- Sponsor-owned vs. CRO-hosted eTMF
- Comparing eTMF options at a glance
- How Kivo supports sponsor-owned TMFs
- Frequently asked questions
- Key takeaway
In the realm of clinical trials, the Trial Master File (TMF) plays a pivotal role in documenting the regulatory and administrative information pertaining to a study. It serves as a comprehensive record of the trial, containing crucial documents such as study protocols, brochures, and regulatory approvals. Traditionally, sponsors have entrusted their TMFs to Contract Research Organizations (CROs) as they had the technology to support the management of the files and were also responsible for managing the various aspects of the trial. However, there are significant advantages to be gained by sponsors who take ownership of their TMF documentation and maintain control over its management.
In this article, we will explore why sponsors should reconsider leaving their TMFs solely in the hands of their CROs and instead opt for a single, centralized system that offers improved quality, effective oversight, process standardization, and efficiency. We will delve into the benefits of having a single source of TMF documentation, simplifying the use of multiple CROs, enhancing quality oversight and control, promoting consistency, and eliminating end-of-study transfers or uncontrolled migrations. Additionally, we will highlight potential issues that can arise when the TMF is left with the CRO, such as rising costs, quality issues, and poor overall document management, including transfers at the end of the study.
Why sponsors should own the TMF
Regulators have long been clear that outsourcing the work does not outsource the accountability. The EMA's reflection paper on TMF management states that when a CRO is involved, "the sponsor is still responsible for the trial and will need to maintain oversight," and that the ultimate responsibility for the quality, integrity, confidentiality and retrieval of archived trial documents resides with the sponsor and investigator (EMA, 2015). The same paper expects inspectors to have direct access to the entire TMF, with access to a live eTMF that is essentially immediate. The newer ICH E6(R3) good clinical practice guideline reinforces the point: sponsors may delegate tasks to a CRO but remain ultimately responsible for the trial, and are expected to show documented, ongoing oversight rather than reconstruct it after the fact. It also shifts the emphasis from "essential documents" to broader "essential records." The EU effective date was July 23, 2025.
Now, let's outline some of the benefits to having your own eTMF System, rather than using the CRO.
Benefits of having your own eTMF System
Single Source for TMF Documentation
One of the key benefits of sponsors retaining control over their TMF is the ability to create an ecosystem of the data that can be the single source of the truth. If all relevant documentation and data is in a single system, this allows for better control and visibility of the information. If both the sponsor and CRO documents are in a centralized repository, sponsors can ensure that they have easy access to all critical TMF content. This approach mitigates the risk of missing documentation, a common issue when the TMF is managed solely by the CRO. The control of the information and quality of the data becomes difficult to manage without direct oversight. Sponsors may be unaware of unnecessary duplication or inefficiencies in the CRO's practices, leading to increased study management expenses. By having control of the TMF, sponsors can implement efficient data management strategies, optimize storage at the end of the study, and eliminate unnecessary costs.
Simplifying the Use of Multiple CROs
In complex clinical trials involving multiple CROs, maintaining consistency is important to ensure documents are filed and managed. Leaving the TMF in the hands of the CROs can result in challenges during the study, especially for handoffs between different CROs or when transitioning at the end of the study. For instance, poor handoffs can lead to critical documents missing or being inaccessible. An illustrative example is when a sponsor received a password-protected thumb drive from their CRO, only to discover that the only person who knew the password had left the company. Such situations can cause significant delays, frustration, and potentially compromise the integrity of the TMF. By maintaining ownership of the TMF, sponsors can establish standardized processes and SOPs that facilitate smooth data sharing between CROs, ensuring proper documentation handoffs and reducing the risk of critical information being lost or inaccessible.
Enhanced Oversight and Control
Taking ownership of the TMF provides sponsors with greater oversight and control over how information is maintained, and quality is more easily managed. Leaving the TMF solely with the CRO can result in suboptimal quality management practices, making it challenging for sponsors to establish and enforce quality requirements. For example, sponsors may face difficulties in obtaining accurate metrics or appropriate access for conducting oversight activities leading to a lack of consistency across studies and vendors. By retaining control of the TMF, sponsors can implement robust quality control measures, establish comprehensive quality requirements, and ensure adherence to regulatory guidelines. This level of control facilitates proactive identification and resolution of issues, minimizing the chances of missing or incomplete documentation, and ensuring the integrity of the TMF. For a closer look at what oversight requires from the system itself, see what an eTMF system needs for real sponsor oversight.
Consistency and Familiarity for Internal Team Members
Having a centralized eTMF system under the sponsor's control offers consistency for internal team members across different studies. This consistency not only simplifies inspection support but also enhances familiarity with the system's functionality and the management of documentation. For instance, during inspections, team members can confidently direct inspectors to the appropriate documentation within the eTMF, as they have a deeper understanding of how the system operates and the filing structure. Additionally, team members can proactively engage with inspectors, discuss the TMF's structure and processes, and respond to inquiries confidently. By maintaining ownership of the TMF, sponsors provide their team members with a familiar and standardized environment, improving efficiency, quality, and enabling effective collaboration during inspections and audits.
Eliminating the Need for End-of-Study Transfers
Leaving the TMF management exclusively with the CRO necessitates the transfer or migration of the TMF once the study concludes and the contractual arrangements for the study have been fulfilled. This process can be plagued with many challenges and risks. For instance, one common issue is the poor handoff of the TMF at the end of the study. As previously mentioned, some sponsors have received password-protected thumb drives with no access to the password, causing significant obstacles in accessing and retrieving TMF's content. Such situations can lead to delays, data loss, and potential compliance issues. By retaining ownership of the TMF, sponsors can mitigate the risk associated with these issues entirely. The TMF remains within the sponsor's controlled system, eliminating the need for end-of-study transfer. This approach ensures that all study-related documentation is readily accessible, facilitating archival for long-term retention, and availability for data reuse for future studies or regulatory submissions. See also our guide to TMF archiving after study closeout.
If you are currently storing your TMF with the CRO and need to migrate, you can read our previous article outlining best practices for TMF Transfer, and/or download our TMF Transfer Checklist.
Sponsor-owned eTMF vs. CRO-hosted eTMF
The table below summarizes how the two models differ on the points sponsors most often weigh. Neither is right for every study; a small, single-CRO Phase 1 may reasonably accept a CRO-hosted TMF, while multi-CRO or multi-study programs usually benefit from ownership.
| Consideration | Sponsor-owned eTMF | CRO-hosted eTMF |
|---|---|---|
| Oversight and visibility | Real-time access to completeness and quality metrics | Depends on the access and reports the CRO provides |
| Inspector access | Sponsor controls and grants it directly | Typically arranged through the CRO |
| End-of-study transfer | None; the TMF stays in place | Migration or export required at closeout |
| Consistency across studies and CROs | One filing structure and process | Varies by CRO and system |
| Cost structure | Platform subscription plus internal TMF ownership | Bundled in CRO fees; transfer and storage costs can appear later |
| Internal effort | Needs a named TMF owner and a routine quality check | Lower day-to-day effort for the sponsor |
For a deeper look at costs and resourcing, see the true cost of building and maintaining an in-house eTMF, and for timing, when and why to implement an eTMF system.
Comparing eTMF Options at a Glance
If you decide to hold the TMF yourself, the next question is which system. The table below profiles four options in the same format. It is not an independent ranking and does not assess implementation quality, market share, or fitness for any particular organization; validate each option against your own requirements, study portfolio, and inspection history.
| Option | Platform scope | Typical fit | Compliance and validation approach |
|---|---|---|---|
| Kivo eTMF | eTMF on one platform with document management, RIM, and QMS; Part 11 e-signature included | Clinical-stage biotech sponsors, from pre-IND through approval, and the CROs and partners that support them | Continuous CSA-aligned validation with each release; SOC 2 Type 2 and ISO 9001 certified |
| Veeva Vault eTMF | eTMF application within the broader Veeva Vault clinical suite | Sponsors and CROs already standardized on Veeva's clinical applications, including larger programs | Vendor-managed, validated cloud environment |
| Montrium eTMF Connect | Dedicated eTMF platform organized around the TMF Reference Model | Pharma and biotech teams evaluating a standalone eTMF outside a larger operational suite | Positioned by Montrium around inspection readiness and sponsor oversight |
| Florence eTMF | eTMF connected to Florence's site-facing eBinders platform | Sponsors and CROs prioritizing document exchange directly with investigator sites | Part 11-oriented electronic records and signatures with role-based access |
Whichever you evaluate, ask each vendor how its system handles inspector access, migration in and out of the system, long-term storage pricing, and validation evidence. For a fuller checklist, see how to select an eTMF system.
How Kivo Supports Sponsor-Owned TMFs
Kivo's eTMF is built for sponsors who want to own the TMF without taking on enterprise overhead, and for the CROs that work alongside them. Relevant capabilities include:
- TMF migration out of a CRO: a validated process that ingests documents, metadata, and audit trails from virtually any TMF platform via secure FTP and recompiles a single unified audit trail. Elevar Therapeutics migrated 19 TMF studies (73,794 documents) in 72 days.
- Inspection readiness: inspector-specific access can be granted in minutes and shows only final document versions, built around the TMF Reference Model.
- Long-term storage: TMFs can be retained for 25+ years with read-only states, preserved audit trails, and quarterly data-integrity checks, with no per-GB or per-study charge.
- Validation handled for you: continuous CSA-aligned validation ships with every release, so your team reviews and approves evidence rather than validating the software itself.
Kivo is rated 4.9/5 on G2 and is used by 200+ sponsor, consultant, and CRO teams. To see how it works for your studies, visit the Kivo eTMF page.
Frequently Asked Questions
Should a sponsor leave the TMF with the CRO?
Usually not as a long-term default. The sponsor remains responsible for the trial and for the TMF's quality and retrievability even when a CRO manages it. Holding the TMF in your own eTMF gives direct oversight and avoids end-of-study transfer risk, though a CRO-hosted TMF can be acceptable for a small, single-CRO study.
What are the pros and cons of an in-house vs. CRO-hosted eTMF?
A sponsor-owned eTMF offers real-time oversight, control of inspector access, and no closeout transfer, but needs someone to own TMF quality and process. A CRO-hosted eTMF reduces internal effort but limits visibility and can create transfer risk and extra cost when the study ends.
What happens to the TMF at the end of a study if the CRO holds it?
The TMF must be transferred or migrated to the sponsor, typically with its metadata and audit trail intact. Poorly planned handoffs, such as an unreadable drive, can cause delays, data loss, and compliance issues. Agree transfer terms in the CRO contract before the study starts.
What resources does a sponsor need to run an eTMF in-house?
A named TMF owner, a filing plan aligned to the TMF Reference Model, a routine quality check for completeness and timeliness, trained users at the sponsor, CRO, and sites, and a validated system with audit trails. Many teams pair the platform with vendor training and support.
Can a sponsor own the TMF when using multiple CROs?
Yes, and it is often where ownership helps most. One sponsor-owned eTMF lets every CRO file into the same structure, which standardizes quality checks and removes the need to reconcile separate systems or transfer multiple TMFs at closeout. Agree filing conventions with each CRO up front.
Key Takeaway
In conclusion, sponsors should carefully consider the advantages of retaining ownership of their TMFs rather than leaving them solely with CROs. By having a TMF system under their control, sponsors can benefit from a single source of documentation, simplified management when outsourcing to multiple CROs, enhanced oversight and quality control, consistency for internal team members, and the elimination of end-of-study transfers. Furthermore, by exploring the potential risk associated with leaving the TMF with the CRO, such as poor management, missing documentation, and issues with handoffs, sponsors can appreciate the importance of taking proactive measures to ensure the integrity, accessibility, and compliance of their TMF.
Ultimately, by retaining control over their TMF, sponsors empower themselves to optimize collaboration with CROs, confidently engage with regulatory authorities, and establish a robust foundation for efficient and compliant TMF management throughout the clinical trial lifecycle.
Ready to start implementing your own eTMF System? Reach out to us!
